(Q38020244)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Second-line systemic therapy for the treatment of metastatic renal cell cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Jens Bedke

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Markus A Kuczyk

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Axel S Merseburger

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

777-785

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

5 February 2020

cites work

1 reference

EAU guidelines on renal cell carcinoma: the 2010 update

21 January 2018

1 reference

Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action

21 January 2018

1 reference

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

21 January 2018

1 reference

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

21 January 2018

1 reference

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression

21 January 2018

1 reference

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

21 January 2018

1 reference

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

21 January 2018

1 reference

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease

21 January 2018

1 reference

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22716494%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference